A genetically determined decrease in apoC-III due to APOC3 loss-of-function mutations resulted in a roughly 3-fold higher fractional clearance rate of VLDL1 apoB100 compared to nonvariant carriers.
Observational (n=12)
No
Does a genetically determined decrease in apoC-III alter the postprandial kinetics of apolipoproteins B48 and B100 in humans?
A genetically determined decrease in apoC-III accelerates lipolysis of triglyceride-rich lipoproteins and increases removal of VLDL remnants, suggesting apoC-III lowering may be beneficial for cardiovascular disease prevention.
Absolute Event Rate: 48.4% vs 13.1%
p-value: p=<0.01
BackgroundApolipoprotein C-III (apoC-III) is a regulator of triglyceride (TG) metabolism, and due to its association with risk of cardiovascular disease, is an emergent target for pharmacological intervention. The impact of substantially lowering apoC-III on lipoprotein metabolism is not clear.MethodsWe investigated the kinetics of apolipoproteins B48 and B100 (apoB48 and apoB100) in chylomicrons, VLDL1, VLDL2, IDL, and LDL in patients heterozygous for a loss-of-function (LOF) mutation in the APOC3 gene. Studies were conducted in the postprandial state to provide a more comprehensive view of the influence of this protein on TG transport.ResultsCompared with non-LOF variant participants, a genetically determined decrease in apoC-III resulted in marked acceleration of lipolysis of TG-rich lipoproteins (TRLs), increased removal of VLDL remnants from the bloodstream, and substantial decrease in circulating levels of VLDL1, VLDL2, and IDL particles. Production rates for apoB48-containing chylomicrons and apoB100-containing VLDL1 and VLDL2 were not different between LOF carriers and noncarriers. Likewise, the rate of production of LDL was not affected by the lower apoC-III level, nor were the concentration and clearance rate of LDL-apoB100.ConclusionThese findings indicate that apoC-III lowering will have a marked effect on TRL and remnant metabolism, with possibly significant consequences for cardiovascular disease prevention.Trial registrationClinicalTrials.gov NCT04209816 and NCT01445730.FundingSwedish Heart-Lung Foundation, Swedish Research Council, ALF grant from the Sahlgrenska University Hospital, Novo Nordisk Foundation, Sigrid Juselius Foundation, Helsinki University Hospital Government Research funds, Finnish Heart Foundation, and Finnish Diabetes Research Foundation.
Taskinen et al. (Tue,) conducted a observational in APOC3 loss-of-function mutation (n=12). APOC3 loss-of-function mutation vs. Nonvariant carriers was evaluated on VLDL1 apoB100 fractional clearance rate (pools/d) (p=<0.01). A genetically determined decrease in apoC-III due to APOC3 loss-of-function mutations resulted in a roughly 3-fold higher fractional clearance rate of VLDL1 apoB100 compared to nonvariant carriers.